NCT00254397View on ClinicalTrials.gov

Melanoma Vaccine With Peptides and Leuprolide

PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Melanoma
Interventions
DRUG

Leuprolide

A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).

BIOLOGICAL

GP100: 209-217(210M) Peptide

1.0 ml subcutaneous injection in extremities.

BIOLOGICAL

MAGE-3 Peptide

1.0 ml subcutaneous injection in extremities.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT00254397 - Melanoma Vaccine With Peptides and Leuprolide | Biotech Hunter | Biotech Hunter